Who owns Vanda Pharmaceuticals Inc. (VNDA)? Elite investor 13F holders
2 tracked elite investors reported holding Vanda Pharmaceuticals Inc as of 2026-06-30, including Renaissance Technologies LLC, GMO. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | VANDA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 21061129.00 USD | 3441361.000000 | Shares | reduce | Original filing |
| Tudor Investment | VANDA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| GMO | VANDA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 173465.00 USD | 28344.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.